Et fase 3-studie af Barzolvolimab hos deltagere med kronisk spontan nældefeber (CSU) (EMBARQ-CSU2)
Et fase 3 randomiseret, dobbeltblindt, placebokontrolleret studie for at vurdere effektiviteten og sikkerheden af Barzolvolimab hos patienter med kronisk spontan nældefeber, som forbliver symptomatisk på trods af H1 antihistaminbehandling (EMBARQ-CSU2)
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.
There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.
Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Charlestown, New South Wales, Australien, 2290
- Novatrials
-
Darlinghurst, New South Wales, Australien, 2010
- Skin and Cancer Foundation - The Skin Hospital
-
Kogarah, New South Wales, Australien, 2217
- St George Dermatology and Skin Cancer Center
-
Westmead, New South Wales, Australien, 2145
- Westmead Hospital
-
-
Queensland
-
Brisbane, Queensland, Australien, 4102
- Princess Alexandra Hospital
-
Coorparoo, Queensland, Australien, 4151
- Cornerstone Dermatology
-
Woolloongabba, Queensland, Australien, 4102
- Veracity Clinical Research Pty Ltd
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- Box Hill Hospital
-
East Melbourne, Victoria, Australien, 3002
- Dr Rodney Sinclair Pty Ltd
-
Melbourne, Victoria, Australien, 3004
- The Alfred Hospital
-
Parkville, Victoria, Australien, 3050
- The Royal Melbourne Hospital
-
-
-
-
-
Dupnitsa, Bulgarien, 2600
- Medical Centre Asklepii OOD
-
Haskovo, Bulgarien, 6300
- Medical Center - Pulmo 2018
-
Lovech, Bulgarien, 5500
- Medical Center Medconsult Pleven
-
Pazardzhik, Bulgarien, 4400
- Multiprofile Hospital for Active Treatment - Pazardzhik AD
-
Plovdiv, Bulgarien, 4002
- University Multiprofile Hospital for Active Treatment Sveti Georgi EAD
-
Rousse, Bulgarien, 7000
- Medical Center Prolet
-
Sevlievo, Bulgarien, 5400
- Medical Center Unimed EOOD
-
Sofia, Bulgarien, 1431
- University Multiprofile Hospital for Active Treatment Aleksandrovska EAD
-
Sofia, Bulgarien, 1527
- University Multiprofile Hospital for Active Treatment "Tsaritsa Yoanna - ISUL"
-
Sofia, Bulgarien, 1431
- Diagnostic and Consultative Center Aleksandrovska EOOD
-
Sofia, Bulgarien, 1680
- Diagnostic-Consultative Centre Convex EOOD
-
Sofia, Bulgarien, 1202
- Diagnostic-consultative center Ascendent EOOD
-
-
-
-
-
Kingston, Canada, K7L 2V7
- Kingston Health Science Center
-
Québec, Canada, G1W4R4
- Centre de Recherche Saint-Louis (Québec)
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3S9
- Laser Rejuvenation Clinics Edmonton D.T. Inc.
-
Edmonton, Alberta, Canada, T6H 4J8
- Vida Clinical Research
-
Edmonton, Alberta, Canada, T6W 0J5
- Rejuvenation Dermatology Edmonton South
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 3C3
- LEADER research
-
London, Ontario, Canada, N6H 5L5
- DermEffects
-
North Bay, Ontario, Canada, P1B 3Z7
- North Bay Dermatology Centre
-
Ottawa, Ontario, Canada, K1H1E4
- Ottawa Allergy Research Corporation
-
Richmond Hill, Ontario, Canada, L4B 1L1
- York Dermatology Clinic & Research Centre
-
Toronto, Ontario, Canada, M2N 3A6
- North York Research Inc.
-
Windsor, Ontario, Canada, N8X 2G1
- Joel Liem Medicine Professional Corporation
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7T0G3
- Saskatoon Dermatology Centre
-
-
-
-
-
Lo Barnechea, Chile, 7691236
- Clinica MEDS La Dehesa
-
Osorno, Chile, 5290000
- Hospital Base San Jose de Osorno
-
Providencia, Chile, 7500000
- Enroll SpA - Dr. Manuel Barros Borgono
-
Recoleta, Chile, 8420000
- Clinica Davila - Recoleta
-
Recoleta, Chile, 8420383
- Centro Internacional de Estudios Clinicos (CIEC)
-
Santiago, Chile, 8350595
- BIOCINETIC Ltda
-
Vitacura, Chile, 7630000
- Dermacross Clinica Dermatologica
-
Viña del Mar, Chile, 2520000
- Medical Skin Center
-
-
-
-
-
Barranquilla, Colombia, 8001
- Centro Integral de Reumatologia Del Caribe
-
Medellín, Colombia, 50012
- Centro de Inmunología y Genética - CIGE S.A.S
-
Medellín, Colombia, 50015
- Hospital General de Medellín Luz Castro de Gutiérrez
-
Medellín, Colombia, 50021
- Fundación Centro de Investigation Clínica CIC
-
Medellín, Colombia, 50010
- Hospital Alma Mater de Antioquia
-
Soledad, Colombia, 83001
- Fundación Hospital Universidad del Norte
-
-
-
-
-
Bristol, Det Forenede Kongerige, BS10 5NB
- Southmead Hospital
-
Cambridge, Det Forenede Kongerige, CB2 0QQ
- Cambridge University Hospitals, Addenbrooke's Hospital
-
Edinburgh, Det Forenede Kongerige, EH4 2XU
- Western General Hospital
-
Glasgow, Det Forenede Kongerige, G51 4TF
- Queen Elizabeth University Hospital
-
High Wycombe, Det Forenede Kongerige, HP11 2QW
- Velocity Clinical Research High Wycombe
-
Leeds, Det Forenede Kongerige, LS9 7TF
- St James's University Hospital
-
London, Det Forenede Kongerige, E1 1FR
- The Royal London Hospital
-
North Finchley, Det Forenede Kongerige, N12 8BU
- Velocity Clinical Research, North London - PPDS
-
Oxford, Det Forenede Kongerige, OX44 9PU
- Virtual Clinical Trials Centre, The Stables
-
Plymouth, Det Forenede Kongerige, PL6 5FP
- University Hospitals Plymouth NHS Trust
-
Reading, Det Forenede Kongerige, RG1 5AN
- Royal Berkshire Hospital
-
Romford, Det Forenede Kongerige, RM1 3PJ
- Velocity Clinical Research - Romford
-
Wakefield, Det Forenede Kongerige, WF1 4DG
- Pinderfields Hospital
-
-
-
-
Alabama
-
Cullman, Alabama, Forenede Stater, 35058
- Allervie Clinical Research - Cullman
-
-
Arizona
-
Litchfield Park, Arizona, Forenede Stater, 85340
- Research Solutions of Arizona PC
-
Scottsdale, Arizona, Forenede Stater, 85258
- Medical Research of Arizona a division of Allergy, Asthma, & Immunology, Assoc. Ltd.
-
Scottsdale, Arizona, Forenede Stater, 85260
- Center for Dermatology & Plastic Surgery
-
-
California
-
Bakersfield, California, Forenede Stater, 93301
- Kern Research, Inc.
-
Los Angeles, California, Forenede Stater, 90057
- LA Universal Research Center, Inc.
-
Los Angeles, California, Forenede Stater, 90025
- California Allergy and Asthma Medical Group
-
Los Angeles, California, Forenede Stater, 90024
- UCLA Clinical Trials Contracts & Strategic Relations
-
Mission Viejo, California, Forenede Stater, 92691
- Allergy and Asthma Associates of Southern Cal
-
Pasadena, California, Forenede Stater, 91107
- Huntington Asthma & Allergy Center
-
San Diego, California, Forenede Stater, 92123
- University Clinical Trials
-
San Diego, California, Forenede Stater, 92120
- WR-MCCR
-
San Diego, California, Forenede Stater, 92120
- Apex Clinical Research
-
Santa Monica, California, Forenede Stater, 90404
- Clinical Science Institute
-
Santa Monica, California, Forenede Stater, 90404
- Raffi Tachdjian MD, Inc
-
-
Colorado
-
Castle Rock, Colorado, Forenede Stater, 80109
- Clarity Dermatology, PLLC
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Asthma and Allergy Associates
-
-
Florida
-
Coral Gables, Florida, Forenede Stater, 33134
- Driven Research LLC
-
Delray Beach, Florida, Forenede Stater, 33484
- Palm Beach Dermatology Group
-
Doral, Florida, Forenede Stater, 33172
- Dolphin Medical Research
-
Miami, Florida, Forenede Stater, 33165
- South FL Clinical Research LLC
-
Miami, Florida, Forenede Stater, 33173
- Dade Florida Clinical Research Center
-
Miami Lakes, Florida, Forenede Stater, 33014
- Deluxe Health Center
-
Orlando, Florida, Forenede Stater, 32807
- Revival Clinical Research
-
Sanford, Florida, Forenede Stater, 32771
- International Clinical Research - FL LLC
-
Tamarac, Florida, Forenede Stater, 33321
- D&H Tamarac Research Center, LLC
-
Tampa, Florida, Forenede Stater, 33613
- University of South Florida
-
Tampa, Florida, Forenede Stater, 33615
- Olympian Clinical Research
-
Tampa, Florida, Forenede Stater, 33609
- MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research
-
Tampa, Florida, Forenede Stater, 33607
- Advanced Clinical Research Institute (ACRI) - Florida
-
Tampa, Florida, Forenede Stater, 33607
- Deluxe Health Center
-
-
Georgia
-
Columbus, Georgia, Forenede Stater, 31904
- Lane Dermatology Research - Centricity - PPDS
-
Macon, Georgia, Forenede Stater, 31217
- Skin Care Physicians of Georgia
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83706
- Treasure Valley Medical Research
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush University Medical Center
-
Normal, Illinois, Forenede Stater, 61761
- Sneeze Wheeze and Itch Associates LLC
-
-
Indiana
-
Plainfield, Indiana, Forenede Stater, 46168
- The Indiana Clinical Trials Center, PC
-
South Bend, Indiana, Forenede Stater, 46617
- South Bend Clinic
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160-8500
- University of Kansas Medical Center
-
-
Kentucky
-
Bowling Green, Kentucky, Forenede Stater, 42104
- Equity Medical
-
Lexington, Kentucky, Forenede Stater, 40509
- Allergy & Asthma Associates
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- Velocity Clinical Research - The Dermatology Clinic - Baton Rouge - PPDS
-
-
Maryland
-
Towson, Maryland, Forenede Stater, 21204
- Continental Clinical Research Solutions, LLC - ClinEdge - PPDS
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham and Women's Hospital
-
-
Michigan
-
Caledonia, Michigan, Forenede Stater, 49316
- Derm Institute of Western Michigan
-
Clarkston, Michigan, Forenede Stater, 48346
- Clarkston Skin Research - Clarkston
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63141
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63141
- Midwest Clinical Research, LLC
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68144
- Skin Specialists PC
-
-
New Jersey
-
Belleville, New Jersey, Forenede Stater, 07109
- Hudson-Essex Allergy
-
Paramus, New Jersey, Forenede Stater, 07652
- Impact Medical / Circuit Clinical
-
Riverdale, New Jersey, Forenede Stater, 07457
- Impact Medical / Circuit Clinical
-
-
New York
-
New York, New York, Forenede Stater, 10128
- OptiSkin Medical
-
New York, New York, Forenede Stater, 10023
- Equity Medical LLC
-
-
Ohio
-
Boardman, Ohio, Forenede Stater, 44512
- Optima Research
-
Columbus, Ohio, Forenede Stater, 43235
- Optimed Research Ltd - ClinEdge - PPDS
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Penn State Health Milton Hershey Med Cen
-
-
Rhode Island
-
Johnston, Rhode Island, Forenede Stater, 02919
- Clinical Partners LLC
-
-
Texas
-
El Paso, Texas, Forenede Stater, 79932
- Western Sky Medical Research
-
Pflugerville, Texas, Forenede Stater, 78660
- Austin Institute for Clinical Research, Inc.
-
San Antonio, Texas, Forenede Stater, 78213
- Rainey & Finklea San Antonio Dermatology
-
-
Utah
-
Murray, Utah, Forenede Stater, 84107
- Allergy Associates of Utah - Sandy
-
West Valley City, Utah, Forenede Stater, 84120
- Kalo Clinical Research
-
-
-
-
-
Tbilisi, Georgien, 0119
- LTD" Healthy Future"
-
Tbilisi, Georgien, 0159
- LTD "Center of Allergy and Immunology"
-
Tbilisi, Georgien, 0179
- David Abuladze Georgian Italian Clinic
-
Tbilisi, Georgien, 0186
- LTD "Multiprofile Clinic Consilium Medulla"
-
-
-
-
-
Amsterdam, Holland, 1105 AZ
- AmdsterdamUMC locatie AMC
-
Roosendaal, Holland, 4708 AE
- Bravis Hospital
-
Utrecht, Holland, 3584 CX
- University Medical Center Utrecht
-
-
-
-
-
Ahmedabad, Indien, 380005
- Panchshil Hospital - Ahmedabad
-
Ahmedabad, Indien, 380016
- B. J. Medical College and Civil Hospital
-
Belagavi, Indien, 590010
- KLES Dr Prabhakar Kore Hospital & Medical Research Centre
-
Bhubaneswar, Indien, 751019
- All India Institute of Medical Sciences
-
Jaipur, Indien, 302017
- Apex Hospitals Pvt Ltd
-
Mysore, Indien, 570001
- K R Hospital
-
Pune, Indien, 411004
- Deenanath Mangeshkar Hospital and Research Centre
-
Vadodara, Indien, 391760
- Sumandeep Vidyapeeth University - Dhiraj Hospital
-
-
Gujarat
-
Surat, Gujarat, Indien, 395002
- Nirmal Hospital PVT LTD
-
Vadodara, Gujarat, Indien, 390001
- Medical College Baroda & SSG Hospital
-
-
Maharashtra
-
Nagpur, Maharashtra, Indien, 440009
- Shree Hospital & Critical Care Centre
-
Nashik, Maharashtra, Indien, 422101
- Assured Care Plus Hospital
-
Pune, Maharashtra, Indien, 411005
- Oyster & Pearl Hospitals
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien, 302012
- Excelcare Hospital
-
-
Uttar Pradesh
-
Kanpur, Uttar Pradesh, Indien, 208002
- G.S.V.M. Medical College - Kanpur
-
-
-
-
-
Genova, Italien, 16132
- IRCCS Ospedale Policlinico San Martino
-
Milan, Italien, 20157
- Asst Fbf Sacco
-
Padova, Italien, 38068
- Azienda Ospedale Università di Padova
-
Rozzano, Italien, 20089
- Humanitas Research Hospital
-
Salerno, Italien, 84131
- AOU San Giovanni di Dio e Ruggi d'Aragona
-
San Donato Milanese, Italien, 20097
- IRCCS Policlinico San Donato
-
Torino, Italien, 10126
- Ospedale San Lazzaro PO Molinette
-
-
-
-
-
Rijeka, Kroatien, 51000
- Special Hospital Medico
-
Zagreb, Kroatien, 10000
- Solmed Clinic
-
-
-
-
-
Kaunas, Litauen, LT-44192
- CD8 Klinika
-
Kaunas, Litauen, LT-49387
- UAB Ausros Medicinos Centras
-
Vilnius, Litauen, LT-08109
- UAB "Alerginių susirgimų diagnostikos ir gydymo centras"
-
Vilnius, Litauen, LT-08406
- Santaros KTC (klinikiniu tyrimu centras)
-
-
-
-
-
Chihuahua City, Mexico, 31200
- Unidad de Investigación Cima S.a
-
Chihuahua City, Mexico, 31203
- Meidadvance Clinical
-
Cuauhtémoc, Mexico, 06100
- Cryptex
-
Guadalajara, Mexico, 44130
- Centro de Investigación Medico Biologica
-
Guadalajara, Mexico, 44340
- CIMET
-
Guadalajara, Mexico, 44670
- Panamerican Guadalajara
-
Monterrey, Mexico, 64718
- Eukarya Pharmasite
-
Morelia, Mexico, 58249
- CECYPE
-
Mérida, Mexico, 97000
- Centro de Desarrollo Biomédico
-
Mérida, Mexico, 97125
- Mérida Investigación Clínica
-
San Juan del Río, Mexico, 76800
- Unidad de Medicina Especializada
-
Veracruz, Mexico, 91900
- FAICIC
-
-
-
-
-
Auckland, New Zealand, 1010
- Optimal Clinical Trials - Central
-
Christchurch, New Zealand, 8013
- Pcrn Chch
-
Dunedin, New Zealand, 9016
- Momentum Clinical Research Dunedin
-
Hamilton, New Zealand, 3200
- Lakeland Clinical Trials - Waikato
-
Nelson, New Zealand, 7011
- velocity Nova Sp. z o.o.
-
Rotorua, New Zealand, 3010
- Pacific Clinical Research Network Rotorua
-
Tauranga, New Zealand, 3110
- Momentum Clinical Research Tauranga
-
Upper Hutt, New Zealand, 5018
- Lakeland Clinical Trials Wellington
-
-
-
-
-
Częstochowa, Polen, 42-217
- Centrum Medyczne Pratia Częstochowa
-
Częstochowa, Polen, 42-202
- Klinika Dermatologii i Dermatologii Onkologicznej
-
Elblag, Polen, 82-300
- Centrum Kliniczno-Badawcze J.Brzezicki,B.Górnikiewicz-Brzezicka, Lekarze Spółka Partnerska
-
Gdansk, Polen, 80-382
- Synexus Polska Sp. z o.o.
-
Grodzisk Mazowiecki, Polen, 05-825
- Mazowieckie Centrum Badań Klinicznych SC IWONA CZAJKOWSKA ANNA PODRAZKA-SZCZEAPANIAK
-
Katowice, Polen, 40-611
- Provita Sp zoo
-
Krakow, Polen, 30-363
- Centrum Medyczne Plejady
-
Krakow, Polen, 31-624
- Malopolskie Centrum Alergologii
-
Krakow, Polen, 30-033
- Centrum Medyczne "All-Med" Badania Kliniczne
-
Lodz, Polen, 92-213
- Uniwersytet Medyczny w Łodzi - Centrum Wsparcia Badań Klinicznych
-
Lublin, Polen, 20-362
- Velocity Nova Sp. z o.o.
-
Lublin, Polen, 20-607
- DERMEDIC Iwona Zdybska
-
Lublin, Polen, 20-412
- Pro Life Medica ETG Lublin
-
Lublin, Polen, 20-753
- LUXDERM Specjalistyczny Gabinet Dermatologiczny Prof. dr hab. n. med. Dorota Krasowska
-
Nowa Sól, Polen, 67-100
- Twoja Przychodnia Nowosolskie Centrum Medyczne
-
Opole, Polen, 45-401
- Uniwersytecki Szpital Kliniczny w Opolu
-
Oświęcim, Polen, 32-600
- Medicome Sp. Z O.O.
-
Poznan, Polen, 60-214
- Centrum Alergologii Teresa Hofman Sp. z.o.o.
-
Poznan, Polen, 60-309
- EMC Instytut Medyczny SA, PL Certus Szpital i Ambulatorium
-
Poznan, Polen, 60-693
- Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus Osrodek Diagnostyki I Terapii Uczulen
-
Rzeszów, Polen, 35-055
- Uniwersytecki Szpital Kliniczny im. Fryderka Chopina w Rzeszowie Klinika Dermatologii i Dermatologii Onkologicznej
-
Rzeszów, Polen, 35-205
- EMED Centrum Usług Medycznych Ewa Śmiałek
-
Tarnów, Polen, 33-100
- ALERGO-MED SPECJALISTYCZNA PRZYCHODNIA LEKARSKA Spolka. z o. o.
-
Warsaw, Polen, 02-677
- ETG Warszawa
-
Warsaw, Polen, 02-672
- Synexus Polska Sp. z o.o.
-
Warsaw, Polen, 00-874
- Medicover Integrated Clinical Services Sp. z o.o. Centrum Medyczne Warszawa
-
-
-
-
-
Bardejov, Slovakiet, 08501
- MAXDERM s.r.o.
-
Bratislava, Slovakiet, 85101
- Derma therapy spol. s.r.o.
-
Košice, Slovakiet, 04022
- ALERSA, sro
-
Trnava, Slovakiet, 91702
- Fakultna nemocnica Trnava
-
-
-
-
-
Barcelona, Spanien, 08003
- Hospital del Mar
-
Cadiz, Spanien, 11009
- Hospital Universitari Puerta del Mar
-
Madrid, Spanien, 28006
- Hospital Universitario de La Princesa
-
Madrid, Spanien, 28041
- Hospital 12 De Octubre
-
Pamplona, Spanien, 31008
- Clinica Universidad Navarra- Pamplona
-
Pozuelo de Alarcón, Spanien, 28223
- Hospital Quironsalud Madrid
-
Seville, Spanien, 41012
- FutureMeds Sevilla
-
Seville, Spanien, 41009
- Hospital universitario Virgen Macarena
-
Torrejón de Ardoz, Spanien, 28850
- Hospital Universitario de Torrejón
-
Valencia, Spanien, 46026
- Hospital Universitari i Politecnic La Fe de Valencia
-
Valencia, Spanien, 46940
- Hospital de Manises
-
-
-
-
-
Bangkok Noi, Thailand, 10700
- Siriraj Hospital
-
Chiang Mai, Thailand, 50200
- Maharaj Nakorn Chiang Mai Hospital
-
Khlong Luang, Thailand, 12120
- Thammasat University Hospital
-
Khon Kaen, Thailand, 40002
- Khon Kaen University
-
-
-
-
-
Sfax, Tunesien, 3029
- Hôpital Hédi Chaker
-
Tunis, Tunesien, 1007
- La Rabta Hospital
-
Tunis, Tunesien, 1008
- Habib Thameur Hospital
-
-
-
-
-
Aachen, Tyskland, 52074
- Universitätsklinikum der RWTH Aachen Hautklinik
-
Bad Bentheim, Tyskland, 48455
- Fachklinik Bad Bentheim
-
Berlin, Tyskland, 10629
- Emovis GmbH
-
Bonn, Tyskland, 53127
- Universitätsklinikum Bonn
-
Dresden, Tyskland, 01307
- Universitätsklinikum Carl Gustav Carus an der TU Dresden
-
Düsseldorf, Tyskland, 40225
- Universitätsklinikum Düsseldorf
-
Essen, Tyskland, 45147
- Universitätsklinikum Essen
-
Hamburg, Tyskland, 20095
- Eurofins bioskin Research Center Dermalology
-
Lübeck, Tyskland, 23538
- UKSH Lübeck, Institut für Entzündungsmedizin
-
Mannheim, Tyskland, 68167
- Universitätsklinikum Mannheim
-
Münster, Tyskland, 48149
- Universitätsklinikum Münster
-
Remscheid, Tyskland, 42897
- Hautarztpraxis Dariusch Mortazawi
-
Tübingen, Tyskland, 72076
- Universitäts-Hautklinik, Studienzentrum Immundermatologie
-
-
-
-
-
Debrecen, Ungarn, 4032
- Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
-
Szeged, Ungarn, 6725
- Szent-Gyorgyi Albert Klinikai Kozpont
-
Szolnok, Ungarn, 5000
- Allergo-Derm Bakos Kft.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
Males and females, >/= 18 years of age.
-
Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).
-
CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:
- The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.
- Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.
- UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.
-
Normal blood counts and liver function tests.
-
Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.
-
Willing and able to complete a daily symptom electronic diary and comply with study visits.
-
Participants with and without prior biologic experience are eligible.
Key Exclusion Criteria:
- Women who are pregnant or nursing.
- Chronic urticaria whose predominant manifestation is due to CIndU.
- Other diseases associated with urticaria.
- Active pruritic skin condition in addition to CSU.
- Medical condition that would cause additional risk or interfere with study procedures.
- Known HIV, hepatitis B or hepatitis C infection.
- Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.
- History of anaphylaxis
- Prior treatment with barzolvolimab
There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: barzolvolimab 150 mg
barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks |
Subcutaneous Administration |
|
Eksperimentel: barzolvolimab 300 mg
barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks |
Subcutaneous Administration |
|
Eksperimentel: Placebo then barzolvolimab 150 mg
Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks. |
Subcutaneous Administration Matching placebo Subcutaneous Administration |
|
Eksperimentel: Placebo then barzolvolimab 300 mg
Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks. |
Subcutaneous Administration Matching placebo Subcutaneous Administration |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS). The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0. |
From Day 1 (first dose) to Day 85 (Week 12)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Percentage of participants with UAS7 ≤ 6 at Week 12
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants with AAS7 > 0 at Day 1 who achieved complete control (AAS7 = 0) at Week 12 Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS) in participants who did not respond to or did not tolerate omalizumab. The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12 in participants who did not respond to or did not tolerate omalizumab. |
From Day 1 (first dose) to Day 85 (Week 12)
|
|
Incidence of Treatment-Emergent Adverse Events
Tidsramme: From Day 1 (first dose) to Day 477 (Week 68)
|
Occurrence of treatment emergent adverse events and serious adverse events during the study. |
From Day 1 (first dose) to Day 477 (Week 68)
|
|
Percentage of patients with UAS7=0 at Week 12
Tidsramme: From Day 1 (first dose) to Day 85 (Week 12)
|
Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12. |
From Day 1 (first dose) to Day 85 (Week 12)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CDX0159-13
- 2024-513210-36-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .